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The phosphoinositide-3 kinase (PI3K) pathway is deregulated in a significant proportion of melanomas, and PI3K
pathway activation in combination with constitutively active mitogen-activated protein kinase signaling shows
synergistic effects in the process of melanoma tumorigenesis. Recently, a tumor suppressor function for the lipid
phosphatase inositol polyphosphate 4-phosphatase type II (INPP4B) has been described in breast and prostate
cancers, with impact on PI3K signaling output. Given the importance of PI3K pathway activity for melanoma
formation and growth, we aimed to assess the role of INPP4B in melanocytic tumors. Our studies in native tumors
suggest that decreased INPP4B expression is an event correlating with tumor progression in melanocytic
neoplasms. We further demonstrate that INPP4B regulates PI3K/Akt signaling and exerts a tumor suppressor
effect, impacting the proliferative, invasive, and tumorigenic capacity of melanoma cells. INPP4B expression in
melanocytic neoplasms may therefore have potential as a biomarker for disease progression and as a modulator
for the prediction of treatment outcome.
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INTRODUCTION
Malignant melanoma is a genetically diverse disease with
singular potential for metastasis at small tumor thicknesses.
Incidence estimates for 2012 in the United States are 76,000
newly arising invasive melanomas, resulting in over 9,000
deaths (Siegel et al., 2012). In clinical practice, the most
important prognostic factor in the absence of systemic disease
remains histopathologic assessment of depth of invasion of
the primary tumor, measured in millimeters (Breslow
thickness); furthermore, the presence or absence of
ulceration and mitotic activity has an impact on prognosis
(Balch et al., 2009). Curative therapy is mainly restricted to
early tumor stages, and despite major advances in the
understanding of melanoma biology few treatment strategies
for advanced-stage disease have proven limited survival
benefits (Kudchadkar et al., 2013).
In cutaneous melanoma, mitogen-activated protein kinase/
extracellular signal–regulated kinase (MAPK/ERK) and phos-
phoinositide-3 kinase/Akt (PI3K) pathway effectors are fre-
quent targets for oncogenic activation (Chin et al., 2006).
Whereas oncogenic v-raf murine sarcoma viral oncogene
homolog B1 (BRAF) and neuroblastoma RAS viral oncogene
homolog (NRAS) gene mutations account for MAPK
hyperactivity in 480% of tumors (Tsao et al., 2004; Curtin
et al., 2005), the important known mechanisms leading to
PI3K pathway activation in melanoma are loss of phosphatase
and tensin homolog deleted on chromosome 10 (PTEN)
protein or function, as well as activation of Akt3 (Stahl
et al., 2004; Madhunapantula and Robertson, 2009). Clinical
significance is evidenced by observations of inverse
correlations between PTEN expression and tumor ulceration,
a known variable for outcome, and pAkt expression with
patient survival (Dai et al., 2005; Mikhail et al., 2005).
PI3Ks may be activated through the small GTPase Ras or
directly upon activation of growth factor receptors, leading to
the generation of second messenger phosphatidylinositol
(3,4,5) trisphosphate, recruitment of Akt and 3-phosphoinosi-
tide-dependent kinase 1 to the plasma membrane, and
subsequent activation of Akt (Cantley, 2002). PTEN
antagonizes Akt signaling through conversion of phosp-
hatidylinositol (3,4,5) trisphosphate to phosphatidylinositol
4,5-bisphosphate by hydrolyzing the D3 position of the
inositol ring (Keniry and Parsons, 2008). Src-homology 2–
containing phosphatases 1 and 2 can dephosphorylate the D5
position of phosphatidylinositol (3,4,5) trisphosphate to pro-
duce phosphatidylinositol 3,4-bisphosphate, and are impli-
cated in mediating PI3K responses downstream of insulin
(Clement et al., 2001; Cantley, 2002). Phosphatidylinositol
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3,4-bisphosphate is the main substrate of the lipid phosphatase
inositol polyphosphate 4-phosphatase type II (INPP4B), for
which a tumor suppressor function through inhibition of PI3K
signaling has recently been described in breast and prostate
cancer (Gewinner et al., 2009; Fedele et al., 2010; Hodgson
et al., 2011). Initially isolated from rat brain (Norris et al.,
1995), early reports suggested a tumor suppressor function of
INPP4B on the basis of increased expression in BCR-ABL
leukemia (Ross et al., 2003), and through small hairpin RNA
(shRNA) screens for targets inhibiting mammary epithelial cell
transformation (Westbrook et al., 2005). Importantly, INPP4B
loss was shown to function in a similar cellular context as
PTEN loss, and was found to activate Akt (Gewinner et al.,
2009; Fedele et al., 2010; Hodgson et al., 2011).
Given the importance of PI3K pathway deregulation for mela-
nomagenesis, we sought to explore whether the loss of INPP4B
can contribute to tumor formation in melanocytic neoplasms.
Our findings suggest a tumor suppressor role for INPP4B in
melanoma, mediated through altered PI3K/Akt signaling.
RESULTS
Loss of INPP4B expression correlates with tumor progression in
melanocytic lesions
We initially compared INPP4B staining in several benign nevi
and primary invasive melanomas. In immunohistochemistry
antibody optimization studies, human breast tissue samples
showed INPP4B expression patterns as described previously
(Fedele et al., 2010; Supplementary Figure S1a online). Two
representative cases of melanocytic tumors are shown in
Figure 1a, demonstrating moderate-to-strong cytoplasmic
staining in a nevus sample but weak/absent INPP4B protein
in primary melanoma. To quantify INPP4B protein in native
tumors, we studied a panel of 59 nevi, 67 primary melanomas,
and 56 melanoma metastases on tissue microarrays. Repre-
sentative cores of 0, 1þ , 2þ , and 3þ INPP4B staining scores
are shown in Supplementary Figure S1b online. Importantly, a
significant difference in INPP4B expression was observed
between nevi and primary melanomas, as well as melanoma
metastases (Figure 1b), with the majority of nevi showing
moderate or strong staining for INPP4B protein. A slightly
higher proportion of primary melanomas retained INPP4B
expression compared with metastases; however, statistical
significance was not reached in this tumor cohort (data not
shown). Whereas none of the 138 nevus tissue cores showed
complete absence of INPP4B protein (grade 0), a significantly
higher proportion of tissue cores from malignant melanocytic
lesions showed low grade 1 or completely absent (grade 0)
INPP4B staining (Figure 1c). Taken together, these findings
suggest that INPP4B protein expression is reduced in malig-
nant melanocytic lesions as compared with nevi.
INPP4B expression levels show no correlation with BRAF/NRAS
mutational status in melanoma cell lines, and moderately
correlate with pAkt expression
We next assessed relative endogenous protein levels of
INPP4B, PTEN, and pAkt in immortalized human melano-
cytes and several melanoma cell lines, representative of three
major categories of mutational profiles: BRAF mutant, NRAS
mutant, and BRAF/NRAS wild type (wt). Interestingly, when
using INPP4B-specific antibody on whole-cell lysates of
melanocytic cells, we consistently detected a protein species
of B85 kDa, the expression of which correlated well with
INPP4B messenger RNA expression levels (Figure 2a). The
expression of INPP4B was variable within BRAF and NRAS
mutant melanomas, as low or absent endogenous INPP4B
protein was seen in WC58 melanoma cells, whereas higher
endogenous levels were found in Colo829, A375, MM415,
MM485, and Mewo melanoma cells. It is noteworthy that very
low INPP4B expression levels were also seen in MM127, an
NRAS mutant melanoma cell line, indicating that loss of
INPP4B is not mutually exclusive with NRAS mutations. We
next asked whether endogenous INPP4B expression correlates
with PTEN and pAkt levels in melanoma. As PI3K is thought to
constitute a RAS effector in melanoma (Posch et al., 2013), for
this analysis NRAS mutant melanoma cell lines were
excluded. Although pAkt levels showed an expected strong
reciprocal expression pattern to relative endogenous PTEN
levels (r¼ 0.7), there was a weaker negative relationship
between INPP4B and pAkt levels (r¼ 0.5), and a weak
positive correlation between INPP4B and PTEN expression
(r¼0.2). This suggests that the relationship between INPP4B
and PI3K pathway activity in melanocytic cells is not absolute
but rather may be modulated by additional factors.
Overexpression of INPP4B is associated with decreased Akt
phosphorylation and with a tumor suppressor phenotype in
melanoma
Next, we stably overexpressed INPP4B in melanoma cell
lines and immortalized human melanocytes (HMEL cells) and
tested their proliferative and migratory potential. INPP4B
levels upon FLAG-INPP4B expression were increased B3 to
6-fold compared with controls (Supplementary Figure S2a
and b online). Importantly, although basal levels of pAktS473
and pAktT308 were not significantly affected (Supplementary
Figure S2b online and not shown), INPP4B overexpression
suppressed epidermal growth factor-stimulated AktS473 phos-
phorylation in BRAF/NRAS wt melanoma cells (Figure 2b).
This effect was diminished in BRAF mutant melanoma cells
(WC58) and was not observed in NRAS mutant cells (MM127)
with low endogenous INPP4B levels (Figure 2b). Furthermore,
BRAF/NRAS wt melanoma cells and human melanocyte cells
overexpressing INPP4B showed decreased proliferation rates
(Figure 2c) and displayed significantly decreased migratory
potential in wound-closure assays (Figure 2d). In BRAF and
NRAS mutant melanoma cells, forced expression of INPP4B
also resulted in a substantial reduction in migratory potential,
but in contrast to wt cell lines their proliferative capacity was
not significantly altered (Figure 2e and Supplementary Figure
S2c online). These findings suggest that constitutive MAPK
pathway activation can outweigh some tumor-suppressive
effects mediated by INPP4B overexpression.
INPP4B knockdown activates Akt and increases the migratory,
invasive, and proliferative capacity in melanoma cells
To further characterize the role of INPP4B in melanocytic
cells, we generated melanoma cell lines with stable INPP4B
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knockdown (Figure 3a). Several distinct INPP4B-specific
shRNAs depleted the 85-kDa protein band on INPP4B
immunoblot in melanocytic cells, as well as the reported
106-kDa band in non-melanocytic (MCF7) breast cancer cells
(Fedele et al., 2010), corresponding to significantly lower
INPP4B messenger RNA expression levels (Figure 3a, and
Supplementary Figure S3a and b online). Importantly, knock-
down of INPP4B increased AktSer473 phosphorylation in
melanoma cells and immortalized human melanocytes
(Figure 3a), whereas pAkt Thr308 levels were only slightly
affected, suggesting that INPP4B loss correlates more strongly
with phosphorylation of Ser473 than Thr308 (Figure 3a). We
then tested the invasive capacity of INPP4B-depleted mela-
noma cells using a modified Boyden chamber assay. As shown
in Figure 3b, INPP4B knockdown in C8161 metastatic
melanoma cells enhanced invasion through basement mem-
brane substrate, supporting a role of INPP4B as a negative
regulator for melanoma cell invasion.
We next tested whether loss of INPP4B affects the migratory
potential of melanocytic cells (Figure 3c and d). Significantly
increased migratory potential on INPP4B knockdown was
seen in BRAF/NRAS wt and mutant melanoma cells and in
HMEL cells, leading to advanced wound closure in vitro
(Figure 3c, upper panels and Supplementary Figure S3c
online). Enhanced migratory effects were comparable to
knockdown of PTEN (Supplementary Figure S3d online).
Intriguingly, the increased migratory potential brought on by
INPP4B knockdown was abrogated by the addition of PI3K
inhibitor LY294002 (Figure 3c, lower panel).
Next, we examined whether INPP4B depletion has an impact
on proliferation. The growth rate in BRAF/NRAS wt mela-
noma cells on INPP4B knockdown was significantly increased,
whereas, interestingly, this effect was subtle in melanoma cells
with oncogenic BRAF or NRAS mutations (Figure 3e).
Taken together, these results support a tumor suppressor
role of INPP4B by modulating the activity of signaling effectors
of the PI3K/Akt pathway in melanoma.
INPP4B exerts tumor-inhibitory effects in vivo
The impact of INPP4B expression on tumorigenicity in vivo
was assessed in mouse xenograft studies. Forced expression of
INPP4B significantly reduced the tumorigenic potential of
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Figure 1. Inositol polyphosphate 4-phosphatase type II (INPP4B) protein is expressed at lower levels in malignant melanocytic tumors as compared with nevi.
(a) INPP4B protein expression in a representative melanocytic nevus (Nevus) and primary melanoma (Prim Mel). Note strong cytoplasmic staining within nevus cells
in the dermis (upper panel), and near-complete absence of staining in a primary melanoma (lower panel). H&E, hematoxylin and eosin. Bar¼ 300mm; original
magnification  100. (b) Comparison of INPP4B protein tissue microarray expression scores between nevi (n¼ 59), primary melanomas (Prim Mel, n¼ 67), and
metastatic melanomas (Met Mel, n¼ 65). Proportions of INPP4B high (expression score 2þ , 3þ ) and INPP4B low (0þ , 1þ ) expressing lesions differed
significantly between nevi and primary melanomas, as well as between nevi and metastatic melanomas. (c) Distribution of final INPP4B staining scores for patient-
derived melanocytic neoplasms.
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melanoma cells and prolonged survival time points at which
animals needed to be killed owing to tumor burden (Figure 4a
and b). Immunohistochemistry in xenografts confirmed over-
expression of INPP4B (2þ to 3þ protein expression levels,
compared with weak cytoplasmic (1þ ) staining in control
tumors, Figure 4c) and, importantly, revealed reduced pAkt
Ser473 levels as compared with controls (Figure 4c). Further-
more, whereas central areas of necrosis were noted in all
tumors, cleaved caspase-3 staining in viable areas was
increased in INPP4B-overexpressing tumors (Figure 4c).
Quantification showed significantly increased cleaved cas-
pase-3 staining, whereas the Ki67 mitotic index was reduced
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Figure 2. Forced expression of inositol polyphosphate 4-phosphatase type II (INPP4B) is associated with reduced pAkt levels, as well as proliferative and
migratory potential of melanocytic cells. (a) Relative endogenous INPP4B, phosphatase and tensin homolog deleted on chromosome 10 (PTEN), and pAkt protein
levels in immortalized human melanocytes (HMEL), and three groups of melanoma cell lines, BRAF mutant, NRAS mutant, BRAF/NRAS wild type (wt; top).
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(EGF)-stimulated Akt phosphorylation levels in BRAF/NRAS wt and mutant melanoma cells overexpressing INPP4B. Representative of three independent
experiments. (c) Proliferative potential of control versus FLAG-INPP4B-expressing BRAF/NRAS wt melanoma cells and HMEL cells; error bars, SD. (d) Migratory
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(Figure 4e). No significant differences were observed in vessel
density (not shown). In reciprocal xenograft experiments,
knockdown of INPP4B in melanoma cells lead to significantly
increased tumorigenic potential (Figure 5a). INPP4B-knock-
down xenografts furthermore showed increased pAkt levels as
compared with control tumors (P¼0.04; Figure 5b and not
shown).
Collectively, these observations further strengthen the
notion of INPP4B functioning as a tumor suppressor in
melanoma.
DISCUSSION
The PI3K pathway is deregulated in a significant proportion of
melanomas, and PI3K pathway activation in combination with
constitutively active MAPK signaling is regarded as a transfor-
mative event (Lin et al., 2008; Dankort et al., 2009). Here we
provide evidence that the lipid phosphatase INPP4B can
function as a tumor suppressor in melanoma, impacting
PI3K/Akt signaling output and the proliferative, migratory,
invasive, and tumorigenic capacity of melanocytic cells.
The assessment of gene expression in native tumors is
critical to determine biologic significance. Using a method
that accounts for intratumoral heterogeneity (Kim et al., 2006),
we assessed INPP4B protein expression in 182 native
melanocytic tumors. By group comparison, primary and
metastatic melanomas showed significantly reduced INPP4B
protein expression compared with melanocytic nevi,
identifying loss of INPP4B as a marker for neoplastic
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progression. These findings furthermore suggest that INPP4B
loss may already be selected for at the stage of primary
melanoma before the onset of metastasis, possibly
contributing to melanocyte transformation in a subset of
tumors. Interestingly, our findings parallel PTEN expression
patterns, with PTEN loss described in B60% of primary
melanomas compared with 8% of nevi (Tsao et al., 2004),
and inversely correlate with increased expression levels of
pAkt (Dhawan et al., 2002; Dai et al., 2005). Mutations
acquired during the process of melanocyte transformation,
when present at similar or higher levels in melanoma
metastases, may indicate genes for which expression
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Figure 4. Inositol polyphosphate 4-phosphatase type II (INPP4B) overexpression inhibits tumorigenesis in a xenograft model. (a) Tumor growth kinetics after
subcutaneous injection of nude mice with C8161 melanoma cells expressing FLAG-INPP4B (n¼ 5) or vector alone (n¼ 5). (b) Kaplan–Meyer survival curves.
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correlates with outcome. The prognostic significance for
primary melanoma outcome will need to be addressed in
future studies; however, associations between decreased
INPP4B expression and decreased (recurrence free) survival
have been found in ovarian and prostate cancer (Gewinner
et al., 2009; Hodgson et al., 2011).
Melanoma is a genetically heterogeneous disease, and
certain combinations of mutational events characterize dis-
tinct genotypes. PTEN loss of function may occur concurrently
with BRAF mutations, whereas both are mostly mutually
exclusive with NRAS mutations (Tsao et al., 2000; Goel
et al., 2006). Because of a functional relationship between
INPP4B and PTEN as PI3K antagonists (Gewinner et al., 2009;
Hodgson et al., 2011), we expected retained INPP4B protein
expression in NRAS mutant melanomas and hypothesized that
INPP4B loss may occur in a subset of BRAF mutant
melanomas. However, we found no correlation between
BRAF/NRAS mutation status and relative INPP4B levels;
specifically, in contrast to the loss of PTEN (Goel et al.,
2006), loss of INPP4B expression does not appear to be mutu-
ally exclusive with NRAS mutations. Moreover, the moderate
inverse correlation between pAktSer473 and endogenous
INPP4B levels, together with a minor association bet-
ween INPP4B and PTEN, suggest that in a subset of
melanomas INPP4B may independently contribute to Akt
regulation. However, because of the limited number of cell
lines tested, further study is necessary to elucidate the relative
contributions of endogenous INPP4B levels on PI3K signaling
output.
Our phenotypic assessment of melanoma cells on altered
INPP4B expression is consistent with the notion of INPP4B
functioning as a tumor suppressor, which mediates effects via
the PI3K/Akt signaling axis. In agreement with observations in
breast cancer (Fedele et al., 2010), we found that epidermal
growth factor-stimulated phosphorylation of Akt was suppre-
ssed upon forced expression of INPP4B. Interestingly, these
effects were most pronounced in BRAF/NRAS wt melanoma
cells, whereas INPP4B knockdown increased Akt phosphory-
lation in melanoma cells with different mutational back-
grounds. Similarly, with regard to proliferative capacity, the
phenotypic impact of altered INPP4B expression appeared to
be diminished in melanoma cells carrying oncogenic BRAF or
NRAS mutations, suggesting that constitutive MAPK and/or
PI3K pathway activity could overcome some INPP4B-
mediated effects.
Akt phosphorylation at residues Thr308 and Ser473 is
thought to be necessary for full activation (Sarbassov et al.,
2005; Engelman, 2009). As has been reported in prostate
cancer cells (Hodgson et al., 2011), we found that in melano-
cytic cells altered INPP4B expression primarily affected Akt
phosphorylation at Ser473, suggesting similar effects across
different cell lineages. Furthermore, the enhanced migratory
capacity of melanoma cells upon INPP4B depletion was
comparable to PTEN knockdown effects and, importantly,
the PI3K inhibitor LY294002, which was shown to decrease
Akt phosphorylation and invasion of melanoma cells with
PTEN loss (Nogueira et al., 2010), abrogated increased
migratory effects of INPP4B knockdown. This further
indicates that INPP4B depletion contributes to the observed
migration phenotype through the PI3K–Akt signaling axis, and
raises the possibility that a subset of melanomas deficient for
INPP4B may be sensitive to PI3K pathway inhibition. It is
noteworthy that PI3K pathway activation and increased
migration on INPP4B knockdown were also seen in immorta-
lized human melanocytes, and, although falling short of a
measure for melanocyte transformation, these effects suggest
that INPP4B loss could exert tumor-promoting effects in the
early stages of melanoma development.
Complementing the effects of altered INPP4B expression we
observed in vitro, the growth-inhibitory effects of INPP4B in
melanoma cells were replicated in a xenograft mouse model,
showing altered tumor growth on INPP4B deregulation with
an impact on Akt phosphorylation.
Taken together, these findings establish INPP4B as a tumor
suppressor in melanoma regulating PI3K/Akt signaling.
Interestingly, immunoblot analysis of whole-cell lysates of
melanocytic cells using INPP4B-specific antibody identified
an additional protein form of B85-kDa molecular weight,
which was absent in MCF7 breast cancer cells and whose
expression was significantly depleted by several different
INPP4B-specific shRNAs. Our findings of the corresponding
reduction in messenger RNA expression levels and INPP4B-
specific depletion of the 106-kDa protein in MCF7 cells as
reported (Gewinner et al., 2009; Fedele et al., 2010) suggest
the possibility of a smaller INPP4B isoform expressed in
melanocytic cells. In this regard, it is of interest that the
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Figure 5. Knockdown of inositol polyphosphate 4-phosphatase type II (INPP4B) promotes tumor growth in vivo. (a) Tumor growth kinetics after subcutaneous
injection of C8161 melanoma cells expressing sh-INPP4B (n¼ 10) or vector control (n¼ 10). (b) Representative images of INPP4B and pAkt (Ser473)
immunohistochemistry on INPP4B-knockdown xenografts and control tumors. Original magnification 400 (left panel), 200 (right panel). Scale bars¼ 150 mm.
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existence of INPP4B splice variants (INPP4Ba and INPP4Bb;
Norris et al., 1997; Ferron and Vacher, 2006), and a shorter
isoform of murine INPP4B (INPP4Bas; Ferron and Vacher,
2006) have been reported, showing differences in tissue distri-
bution for individual INPP4 phosphatase proteins. Additional
studies are needed for further characterization; however, our
results demonstrate that INPP4B-specific depletion of the 85-
kDa protein form correlates with PI3K pathway activation and
a more aggressive phenotype in melanoma cells. Furthermore,
knockdown of the 85-kDa protein and overexpression of the
106-kDa protein forms in melanoma cells affect Akt
phosphorylation in a manner described for the 106-kDa
protein in breast and prostate cancer (Gewinner et al., 2009;
Fedele et al., 2010; Hodgson et al., 2011), suggesting syner-
gistic and tumor-inhibitory functions of both variants with
regard to PI3K pathway activity. Tumor-suppressive effects
mediated by INPP4B would therefore be expected to be
reflected by immunohistochemical assessment of both
protein forms in native melanocytic tumors, as performed in
our tumor collection. Whether these proteins exhibit functio-
nal differences in other cellular contexts or show preferential
affinity to specific substrates awaits further study.
Here we provide evidence that INPP4B acts as a tumor
suppressor in melanoma with an impact on PI3K/Akt signaling
output. Currently unanswered is the question of INPP4B gene
expression regulation in melanoma. Loss of heterozygosity at
the INPP4B gene locus has been described (Gewinner et al.,
2009), suggesting that decreased INPP4B expression as
observed in our collective of patient-derived primary and
metastatic melanomas may, in part, be due to only one active
allele. In addition, as epigenetic silencing can account for the
inactivation of PTEN, as well as for the recently described
tumor suppressor phosphatidylinositol 4,5-bisphosphate 5-
phosphatase in melanoma (Mirmohammadsadegh et al.,
2006; Ye et al., 2013), it remains to be determined whether
similar mechanisms contribute to INPP4B gene regulation.
Furthermore, an important question is whether INPP4B loss
cooperates with PTEN deficiency in melanoma. A previous
study found a significant positive correlation between loss of
INPP4B and PTEN in breast cancer (Fedele et al., 2010),
where PTEN-null tumors with high pAkt levels frequently
showed INPP4B loss. Given the importance of PI3K pathway
hyperactivation and frequent PTEN inactivation in melanoma,
we anticipate additive tumor-promoting effects in
combination with INPP4B loss.
Finally, PI3K pathway activation recently gained signifi-
cance as a mediator of resistance to targeted therapy. Specifi-
cally, enhanced insulin-like growth factor-1 receptor/PI3K
signaling was identified as one mechanism of resistance to
selective BRAF inhibitors (Villanueva et al., 2010), and com-
bined treatment strategies targeting MEK and PI3K are being
tested in clinical trials (Nikolaou et al., 2012). Given the
differential extent to which altered INPP4B expression
impacts on the phenotype of BRAF/NRAS wt, BRAF mutant,
and NRAS mutant melanoma cells, studying the possible role
of INPP4B loss in modulating drug resistance will be critical to
predict response rates for tumors with multiple coexistent
aberrations.
MATERIALS AND METHODS
Patient samples and tissue microarrays
Paraffin blocks from 59 nevi, 67 primary melanomas, and 56
melanoma metastases were retrieved from archival material at
Columbia University (New York, NY) and the Fachklinik Hornheide
at University Muenster (Muenster, Germany). Hormone receptor–
negative breast adenocarcinoma and normal human breast tissue
samples were obtained from the Columbia University Tissue Bank.
All studies were approved by corresponding Institutional Review
Boards. To reflect intratumoral heterogeneity on tissue microarrays,
for each tumor a dermatopathologist (BAH) reviewed hematoxylin
and eosin–stained sections to identify three distinct areas of
representative lesional tissue, and three separate 0.6-mm-diameter
tissue cores were assembled into recipient paraffin blocks using a
standard manual tissue array instrument (Beecher Instruments,
Silver Spring, MD).
Immunohistochemistry
Immunohistochemistry was performed according to standard proce-
dures. Antigen retrieval was performed in 10 mM citrate buffer, pH
6.0, at 99 1C for 15 minutes. Incubation with primary antibody was
performed overnight at 4 1C using antibodies against INPP4B (4039,
1:150; Cell Signaling, Danvers, MA), Ki67 (1:200; Cell Marque,
Rocklin, CA), cleaved caspase-3 (1:50; Abcam, Cambridge, MA),
CD31 (1:600; Dako, Carpinteria, CA), and pAkt (Ser473, Cell
Signaling 3787, 1:50). Negative controls without primary antibody
were included in all immunohistochemistry batches.
Semiquantitative analysis. INPP4B expression on tissue cores
was assessed independently by two investigators (BAH and KG)
blinded to study groups and to triplicate core distribution on the
arrays, using a four-tier scoring system (Kim et al., 2006). Staining
intensity was graded as 0 (negative), 1þ (weak cytoplasmic blush
in the majority of tumor cells, moderate staining ino20% of
tumor cells), 2þ (moderate cytoplasmic staining in the majority
of tumor cells, strong staining ino20% of tumor cells), or 3þ
(strong cytoplasmic staining in the majority of tumor cells). Each
case was assigned the highest score from among its independent
cores (Kim et al., 2006). Where final grading differed between the
two observers, a consensus score was determined by joint review.
For quantification of pAkt and caspase-3 staining, micrographs of
five random fields of viable tumor were assessed using NIH
ImageJ (http://rsb.info.nih.gov/ij/).
Cell lines and reagents
Melanoma cell lines A375, Colo829, and Mewo, as well as MCF7
human mammary adenocarcinoma cells, were from the ATCC.
WC58 and WC62 melanoma cells were from Coriell Cell Reposi-
tories, Camden, NJ. MM127, MM415, and MM485 were from Cell
Bank of Australia, Westmead, NSW, Australia. C8161 melanoma
cells were a kind gift from Dr Mary Hendrix, Northwestern Uni-
versity, Chicago, IL. hTERT/CDK4(R24C)/p53DD immortalized
human melanocytes were a kind gift from Dr Hans Widlund, Harvard
University, Boston, MA. All cells were cultured in RPMI (Life
Technologies, Grand Island, NY), supplemented with 10% fetal
bovine serum (Life Technologies) and 1% penicillin/streptomycin
(Life Technologies), except for immortalized human melanocytes,
which were cultured in Ham’s F10 medium (Sigma, St Louis, MO).
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For epidermal growth factor-dependent pAkt assessment, cells were
serum starved for 24 h before treatment with 10 ng ml 1 epidermal
growth factor (PeproTech, Rocky Hill, NJ).
Plasmids, viral infections
Lentiviral INPP4B sh-pLKO clones TRCN0000052721 and
TRCN0000379677 were from the RNAi consortium. ShPTEN-pLKO
was a kind gift from Dr Ramon Parsons, Columbia University. Human
INPP4B complementary DNA was obtained from Open Biosystems
(Huntsville, AL) and PCR-amplified using primers F50-CTAGGT
TAACGCCACCATGGACTACAAAGACGATGACGACAAGGAAATT
AAAGAGGAAGGGGC-30 and R50-CTAGGTTAACTTAGGTGTCA
GCTTTTCCAT-30. The PCR product was cloned into pLHCX
(Clontech, Mountain View, CA) with HpaI to create pLHCX-
FLAG-INPP4B, and the final product was sequence verified. For
virus production, HEK293T cells were cotransfected with pLKO,
pMDLg/pRRE, pRSV-Rev, and pMD2.G (Addgene, Cambridge, MA,
plasmids 12251, 12253, 12259 (Dull et al., 1998)), or pLHCX/
AmphoPack (Clontech, Mountain View, CA) using FuGene6
according to the manufacturer’s protocol (Roche USA, New York,
NY). Filtered conditioned medium was used to infect cultured
melanocytes and melanoma cells in the presence of 2.5mg ml 1
Polybrene (Sigma). Twenty four hours after infection, selection was
started with appropriate antibiotics (pLKO: puromycin, 2mg ml 1;
pLHCX: hygromycin, 50mg ml 1, Invitrogen).
Immunoblot analysis
Exponentially growing cells were collected in lysis buffer contain-
ing 50 mMTris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% octylphe-
noxy polyethoxyethanol, 10 mM betaglycerophosphate, 50 mM
sodium fluoride, 1 mM sodium orthovanadate, 1 ng ml 1 leupeptin,
1 ng ml 1 aprotinin, 1 ng ml 1 pepstatin A, 1 ng ml 1 4-(2-ami-
noethyl)benzenesulfonyl fluoride hydrochloride), and 10 nM Caly-
culin A (Sigma). Twenty micrograms of protein were resolved by
SDS–PAGE, transferred to polyvinylidene difluoride membranes,
and immunoblotted with antibodies to INPP4B (4039), Akt, pAkt
Ser473, pAkt Thr308, p-ERK1/2, ERK1/2, b-tubulin, glyceralde-
hyde-3-phosphate dehydrogenase, and PTEN (all Cell Signaling).
The intensity of bands was quantified using ImageJ.
Modified Boyden chamber assays
Invasive capacity was assessed using the 24-well QCM Collagen Cell
Invasion Assay (8mm pore size, Millipore, Billerica, MA), according to
the manufacturer’s instructions. Briefly, cells were serum starved for
24 hours and 250 000 cells were seeded in serum-free medium into
the upper chamber. Fetal calf serum (10%) in the lower chamber
served as a chemoattractant. Cells were allowed to invade for
20 hours, detached from the bottom membrane, lysed, and stained
with fluorescent dye (CyQUANT GR, Molecular Probes, Eugene, OR).
Cell numbers were assessed using a fluorescence plate reader with a
480/520-nm filter set. Raw fluorescence values were normalized to
reference controls in the absence of chemoattractant.
Wound-closure assays
Cells expressing INPP4B shRNA, full-length INPP4B, or vector control
were grown to confluent monolayers, and a scratch wound was
introduced using a p10 pipette tip. Photographs were taken after
1 hour and after 8 hours, and the percentage wound closure was
calculated using ImageJ. For rescue experiments, LY294002 was
added at a final concentration of 10mM.
Xenograft experiments
Animal procedures followed protocols approved by the Institutional
Animal Care and Use Committee. Melanoma cells (2 106) expres-
sing control vector FLAG-INPP4B or INPP4B shRNA were subcuta-
neously injected into the flanks of 6-week-old female nude mice
(Taconic Farms, Hudson, NY). Tumor growth was assessed every 3
days over a period of 2 months, and mice were euthanized when
tumor volume reached 1 cm3. On termination of experiments, tumors
were collected and subjected to immunohistochemical analysis as
described above.
Quantitative reverse-transcriptase–PCR
Semiquantitative reverse-transcriptase–PCR using FastStart SYBR-
Green (Roche) was performed using the following primers: INPP4B,
F50-GCCGACCAC ATCACCACAG-30, R50-TTTCCGCTCACACTTTC
CG-30; beta-actin, F50-AACCTAACTTGCGCAGAAAAC-30 and R50-
TTTACACGAAAGAACTGCTATC-30 (Gewinner et al., 2009).
Statistical methods
Differences in INPP4B protein expression were calculated for
INPP4B low (0/1þ ) and INPP4B high (2þ /3þ ) lesions by group
comparison between nevi, primary melanomas, and melanoma
metastases using Fisher’s exact test. Correlation between relative
protein expression levels was performed using Pearson’s correlation
coefficient. Analysis of wound-closure assay, collagen invasion
assay, xenograft studies, pAkt, Ki67, and caspase-3 studies was
carried out using Student’s t-test.
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